drugset / Trial / NCT00850785

Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer

NCT00850785

NaSingle-groupOpen-labelTreatment

Summary

This is a pilot single institution study of DRibble vaccination + GM-CSF in patients with stage IIIB or IV NSCLC who have undergone 0-1 chemotherapy regimens for metastatic disease. The primary objective of this trial is to evaluate immune responses induced by autologous DRibble vaccine in vivo and in vitro and against autologous and allogeneic lung cancer cells.

Timeline

Start
2009-01
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DRibble vaccine Vaccine 5e+06 cells Intrathecal
Subject DRibble vaccine Vaccine 2e+07 cells Intrathecal
Subject Docetaxel Small molecule 75 mg/m2
Background sargramostim Protein / enzyme biologic 50 ug Subcutaneous